Aspire Biopharma Holdings (ASBP) Total Non-Current Liabilities (2022 - 2025)
Aspire Biopharma Holdings' (ASBP) quarterly Total Non-Current Liabilities came in at $7.6 million in Q4 2025, up 543.26% year-on-year from $1.2 million in Q4 2024, and down 10.88% on a QoQ basis from $8.6 million in Q2 2025.
Aspire Biopharma Holdings (ASBP) Total Non-Current Liabilities (2022 - 2025) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 4 years of Total Non-Current Liabilities data on file, last reported at $7.6 million in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities rose 543.26% year-over-year to $7.6 million in Q4 2025; TTM through Dec 2025 was $7.6 million, a 543.26% increase from a year earlier, with the FY2025 full-year figure at $7.6 million, up 543.26% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $7.6 million, down from $8.6 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for ASBP reached as high as $11.1 million in Q4 2022 and fell as low as -$449214.0 in Q3 2024.
- Historically, Total Non-Current Liabilities has averaged $4.5 million across 4 years, with a median of $4.0 million in 2024.
- Across the five-year window, Total Non-Current Liabilities sank 242.01% in 2024 and soared 543.26% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $11.1 million in 2022, then plunged by 97.77% to $247480.0 in 2023, then soared by 380.39% to $1.2 million in 2024, then surged by 543.26% to $7.6 million in 2025.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $7.6 million in Q4 2025, $8.6 million in Q2 2025, and $8.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Aspire Biopharma Holdings | 1.21 Mn | -619,284.29 | 5,750.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.65 Mn |
| Jun 30, 2025 | 8.58 Mn |
| Mar 31, 2025 | 8.04 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | -449,214.00 |
| Jun 30, 2024 | 5.79 Mn |
| Mar 31, 2024 | 2.18 Mn |
| Dec 31, 2023 | 247,480.00 |
| Sep 30, 2023 | 316,316.00 |
| Dec 31, 2022 | 11.12 Mn |